## SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

### **SCHEDULE 13D/A**

Under the Securities Exchange Act of 1934 (Amendment No. 2)\*

## Inozyme Pharma, Inc.

(Name of Issuer)

Common Stock, par value \$0.0001 (Title of Class of Securities)

45790W108 (CUSIP Number)

Robert Hopfner Pivotal bioVenture Partners Fund I U.G.P. Ltd 501 2nd Street, Suite 200 San Francisco, CA 94107 (415) 697-1002

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

May 12, 2023 (Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this
schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. $\Box$

**Note**: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Section 240.13d-7 for other parties to whom copies are to be sent.

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1.	Names of Reporting Persons.				
	Pivotal bioVenture Partners Fund I, L.P.				
2.			ppropriate Box if a Member of a Group (See Instructions)		
	(a) □ (b) ⊠				
3.	SEC U	Ico On	1		
3.	SEC C	se On	ny .		
4.	Source	of Fu	ands (See Instructions)		
	MC				
5.	WC	if Dic	closure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)		
٥.	CHECK	מע וו	closure of Legal Froceedings is Required Fursuant to Items 2(u) of 2(e)		
6.	Citizei	nship o	or Place of Organization		
	Cayma				
		7.	Sole Voting Power		
Nui	mber of		0		
	hares	8.	Shared Voting Power		
	eficially ned by				
	Each		2,804,062		
	porting	9.	Sole Dispositive Power		
	erson With		0		
	vviui	10.	Shared Dispositive Power		
			2,804,062		
11.	Aggre	gate A	amount Beneficially Owned by Each Reporting Person		
	2,804,	062			
12.			Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)		
13.	Percen	t of C	lass Represented by Amount in Row (11)		
	6.4%				
14.		of Reno	orting Person (See Instructions)		
	7.5	Р			
	PN				

1.	Names of Reporting Persons.				
	Pivotal bioVenture Partners Fund II, L.P.				
2.	Check the Appropriate Box if a Member of a Group (See Instructions)  (a) □ (b) ⊠				
3.	SEC U	Jse On	ly		
4.	Source	e of Fu	inds (See Instructions)		
	WC				
5.	Check	if Dis	closure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)		
6.	Citize	nship o	or Place of Organization		
	Cayma	an Isla	nds		
	J	7.	Sole Voting Power		
NI	h f				
	mber of Shares	0			
Ben	eficially	8.	Shared Voting Power		
	vned by		857,456		
Each Reporting		9.	Sole Dispositive Power		
Person With			0		
	vviui	10.	Shared Dispositive Power		
			857,456		
11.	Aggre	gate A	Amount Beneficially Owned by Each Reporting Person		
	857,45	6			
12.			Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)		
13.	Percen	t of C	lass Represented by Amount in Row (11)		
	1.9%				
14.		of Repo	orting Person (See Instructions)		
	Dr.	-			
	PN				

1.	Names of Reporting Persons.				
	Pivota	l bioV	enture Partners Fund II G.P. Ltd		
2.					
3.	SEC U	Jse On	lly		
4.	Source	of Fu	ands (See Instructions)		
	AF				
5.	Check	if Dis	closure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)		
6.	Citize	nship (	or Place of Organization		
	Cayma				
		7.	Sole Voting Power		
Number of			0		
Ben	hares eficially	8.	Shared Voting Power		
	ned by Each		857,456		
Re	porting	9.	Sole Dispositive Power		
	erson With		0		
		10.	Shared Dispositive Power		
			857,456		
11.	Aggre	gate A	Amount Beneficially Owned by Each Reporting Person		
	857,45	66			
12.	Check	if the	Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)		
13.	Percen	t of C	lass Represented by Amount in Row (11)		
	1.9%				
14.	Type o	f Rep	orting Person (See Instructions)		
	PN				

1.	Names of Reporting Persons.				
	Pivotal bioVenture Partners Fund I G.P., L.P.				
2.			ppropriate Box if a Member of a Group (See Instructions)		
	(a) 🗆	(l	o) ⊠		
3.	SEC U	Ico On	lv.		
٥.	SEC C	se On	ny .		
4.	Source	of Fu	ands (See Instructions)		
	AF				
5.		if Dic	closure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)		
5.	GHEEK	11 1515	crosure of Degai Frocecumgs is required Furstame to hems 2(a) or 2(c)		
6.	Citize	nship o	or Place of Organization		
	Cayma	n Icla	nde		
	Cayin	7.	Sole Voting Power		
	nber of		0		
	hares eficially	8.	Shared Voting Power		
Ow	ned by		2,804,062		
	Each	9.	Sole Dispositive Power		
	porting erson	•			
	With		0		
		10.	Shared Dispositive Power		
			2,804,062		
11.	Aggre	gate A	Amount Beneficially Owned by Each Reporting Person		
	2,804,062				
12.	Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)				
13.	_	t of C	lass Represented by Amount in Row (11)		
4.	6.4%	C.D.			
14.	Type o	t Kep	orting Person (See Instructions)		
	PN				

1.	Names of Reporting Persons.				
	Pivota	l bioV	enture Partners Fund I U.G.P. Ltd		
2.	Check the Appropriate Box if a Member of a Group (See Instructions)  (a) □ (b) ⊠				
3.	SEC U	Jse On	lly		
4.	Source	e of Fu	ands (See Instructions)		
	WC				
5.	Check	if Dis	closure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)		
6.	Citize	nship (	or Place of Organization		
	Cayma	an Isla	nds		
		7.	Sole Voting Power		
	mber of		0		
	hares eficially	8.	Shared Voting Power		
Ow	ned by Each		2,804,062		
Re	porting	9.	Sole Dispositive Power		
	erson With		0		
		10.	Shared Dispositive Power		
			2,804,062		
11.	Aggre	egate A	Amount Beneficially Owned by Each Reporting Person		
	2,804,	062			
12.	Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)				
13.	Percen	t of C	lass Represented by Amount in Row (11)		
	6.4%				
14.	Type o	f Rep	orting Person (See Instructions)		
	CO				
	· <u></u>				

1.	Names of Reporting Persons.				
	Pivotal Partners Ltd				
2.					
3.	SEC U	Jse On	aly		
4.	Source	e of Fu	ands (See Instructions)		
	AF				
5.		if Dis	closure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)		
6.	Citize	nship (	or Place of Organization		
	Cayma	an Isla	nds		
	24,5	7.	Sole Voting Power		
	nber of hares		0		
	eficially	8.	Shared Voting Power		
Ow	ned by Each		3,661,518		
	porting	9.	Sole Dispositive Power		
	erson		0		
`	With	10.	Shared Dispositive Power		
		10.			
			3,661,518		
11.	Aggre	egate A	Amount Beneficially Owned by Each Reporting Person		
	3,661,	51Ω			
12.			Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)		
12.	Check if the Aggregate Amount in Now (11) Excludes Certain Shares (See instructions)				
13.	Percer	t of C	lass Represented by Amount in Row (11)		
	8.3%				
14.		f Rep	orting Person (See Instructions)		
	CO				

1.	Names of Reporting Persons.				
	Pivotal Life Sciences Holdings Limited				
2.					
3.	SEC U	Jse On	lly		
4.	Source	of Fu	ands (See Instructions)		
	AF				
5.	Check	if Dis	closure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)		
6.		_	or Place of Organization		
	Cayma		Sole Voting Power		
N	nber of	7.			
	hares	0			
Ben	eficially ned by	8.	Shared Voting Power		
	Each		3,661,518		
	porting	9.	Sole Dispositive Power		
	erson With		0		
		10.	Shared Dispositive Power		
			3,661,518		
11.	Aggre	gate A	Amount Beneficially Owned by Each Reporting Person		
	3,661,	518			
12.	Check	if the	Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)		
13.	Percen	t of C	lass Represented by Amount in Row (11)		
	8.3%				
14.	Type o	f Rep	orting Person (See Instructions)		
	CO				

1.	Names of Reporting Persons.				
	Nan Fung Life Sciences Holdings Limited				
2.	Check the Appropriate Box if a Member of a Group (See Instructions)  (a) □ (b) ⊠				
3.	SEC U	se Onl	y		
4.	Source	of Fur	nds (See Instructions)		
	AF				
5.	Check	if Disc	closure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)		
6.	Citizen	ship o	r Place of Organization		
	British		Islands		
		7.	Sole Voting Power		
	mber of		0		
	Shares eficially	8.	Shared Voting Power		
	vned by Each		3,661,518		
Re	porting	9.	Sole Dispositive Power		
	erson With		0		
		10.	Shared Dispositive Power		
			3,661,518		
11.	Aggre	gate A	mount Beneficially Owned by Each Reporting Person		
	3,661,5	18			
12.	Check i	if the A	Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)		
13.	Percent	of Cla	ass Represented by Amount in Row (11)		
	8.3%				
14.	Type of	Repo	rting Person (See Instructions)		
	СО				

1.	Names of Reporting Persons.				
	NF Investment Holdings Limited				
2.	Check the Appropriate Box if a Member of a Group (See Instructions)  (a) □ (b) ⊠				
3.	SEC U	se Onl	y		
4.	Source	of Fur	nds (See Instructions)		
	A.E.				
5.	AF Check i	f Disc	closure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)		
٥.	CHECK	11 10130	nosure of Eegal Proceedings is required 1 distant to hems 2(a) of 2(c)		
6.	Citizen	ship o	r Place of Organization		
	Britich	Virgin	Islands		
	Diffish	7.	Sole Voting Power		
	mber of Shares	_	0		
	neficially	8.	Shared Voting Power		
	vned by		3,661,518		
Each Reporting		9.	Sole Dispositive Power		
F	Person				
	With	10.	0 Shared Dispositive Power		
		10.	Shaled Dispositive Power		
			3,661,518		
11.	Aggreg	gate A	mount Beneficially Owned by Each Reporting Person		
	3,661,5	1Ω			
12.					
	Check if the 11881egate 1 mount in 10 m (11) Excludes Certain States (See Instituctions)				
13.	Percent	of Cla	ass Represented by Amount in Row (11)		
	8.3%				
14.		Repo	rting Person (See Instructions)		
	60				
	CO				

1.	Names of Reporting Persons.				
	Nan Fung Group Holdings Limited				
2.	Check the Appropriate Box if a Member of a Group (See Instructions)  (a) □ (b) ⊠				
3.	SEC U	se Onl	y		
4.	Source	of Fur	nds (See Instructions)		
	AF				
5.	Check	if Disc	closure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)		
6.	Citizen	ship o	r Place of Organization		
	British		Islands		
		7.	Sole Voting Power		
	mber of		0		
	Shares reficially	8.	Shared Voting Power		
	vned by Each		3,661,518		
Re	porting	9.	Sole Dispositive Power		
	erson With		0		
		10.	Shared Dispositive Power		
			3,661,518		
11.	Aggre	gate A	mount Beneficially Owned by Each Reporting Person		
	3,661,5	18			
12.	Check i	f the A	Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)		
13.	Percent	of Cla	ass Represented by Amount in Row (11)		
	8.3%				
14.	Type of	Repo	rting Person (See Instructions)		
	СО				

#### Item 3. Source and Amount of Funds or Other Consideration

Item 3 is amended and supplemented as follows:

Between May 11, 2023 and May 12, 2023 Pivotal and Pivotal II acquired 447,932 shares of Common Stock in a series of open market purchases for an aggregate purchase price of \$2,849,997.90.

#### Item 5. Interest in Securities of the Issuer

Item 5 is amended and supplemented as follows:

- (a) The information set forth in rows 11 and 13 of the cover pages to this Schedule 13D is incorporated by reference. The percentage set forth in row 13 is based on 44,035,322 outstanding shares of Common Stock, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 9, 2023.
- (c) On May 11, 2023, Pivotal acquired 31,319 shares of Common Stock and Pivotal II acquired 187,911 shares of Common Stock. The shares of Common Stock were purchased for \$6.48 per share and an aggregate purchase price of \$1,420,610.40. On May 12, 2023, Pivotal acquired 32,671 shares of Common Stock and Pivotal II acquired 196,031 shares of Common Stock. The shares of Common Stock were purchased for \$6.25 per share and an aggregate purchase price of \$1,429,387.50.

#### **SIGNATURES**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: May 23, 2023

#### PIVOTAL BIOVENTURE PARTNERS FUND I, L.P.

## By: PIVOTAL BIOVENTURE PARTNERS FUND I G.P., L.P.

Its General Partner,

# By: PIVOTAL BIOVENTURE PARTNERS FUND I U.G.P. LTD

Its General Partner,

By: /s/ Robert Hopfner

Robert Hopfner Authorized Signatory

#### PIVOTAL BIOVENTURE PARTNERS FUND II, L.P.

# By: PIVOTAL BIOVENTURE PARTNERS FUND II G.P. LTD

Its General Partner,

By: /s/ Peter Tuxen Bisgaard

Peter Tuxen Bisgaard

Director

## PIVOTAL BIOVENTURE PARTNERS FUND II G.P. LTD

By: /s/ Peter Tuxen Bisgaard

Peter Tuxen Bisgaard

Director

## PIVOTAL BIOVENTURE PARTNERS FUND I G.P.,

# By: PIVOTAL BIOVENTURE PARTNERS FUND I U.G.P. LTD

Its General Partner,

By: /s/ Robert Hopfner

Robert Hopfner Authorized Signatory

# PIVOTAL BIOVENTURE PARTNERS FUND I U.G.P. LTD

By: /s/ Robert Hopfner

Robert Hopfner Authorized Signatory

#### PIVOTAL PARTNERS LTD

By: /s/ Sun Xintong

Name: Sun Xintong Title: Director

#### PIVOTAL LIFE SCIENCES HOLDINGS LIMITED

By: /s/ Sun Xintong
Name: Sun Xintong

Title: Director

#### NAN FUNG LIFE SCIENCES HOLDINGS LIMITED

By: /s/ Sun Xintong

Sun Xintong Director

### NF INVESTMENT HOLDINGS LIMITED

/s/ Tang Chun Wai Nelson Tang Chun Wai Nelson By:

Director

#### NAN FUNG GROUP HOLDINGS LIMITED

/s/ Tang Chun Wai Nelson By:

Tang Chun Wai Nelson

Director